Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: HER2 Positive Breast Carcinoma|Recurrent Breast Carcinoma|Stage IIIB Breast Cancer AJCC v7|Stage IIIC Breast Cancer AJCC v7|Stage IV Breast Cancer AJCC v6 and v7
Interventions: DRUG: Capecitabine|BIOLOGICAL: Cixutumumab|DRUG: Lapatinib Ditosylate|OTHER: Quality-of-Life Assessment
Sponsor: National Cancer Institute (NCI)
Collaborators: SWOG Cancer Research Network